ModerateMacrolide antibiotic×Atypical antipsychotic – thienobenzodiazepine
Updated · Methodology
Mechanism
Erythromycin prolongs the QT interval on the electrocardiogram, and torsade de pointes and deaths have been reported with it (erythromycin labels). In olanzapine clinical trials, marked prolongation of the corrected QT interval (QTc) to 500 ms or more was uncommon, in 0.1–1% of patients. Olanzapine did not differ significantly from placebo in related cardiac events. After marketing, sudden cardiac death has been reported in people taking olanzapine (olanzapine labels). Taken together, the effects of the two drugs on the heart may add up. The labels of both call for caution with other drugs that prolong the QT interval. The documents say nothing about erythromycin changing olanzapine levels. The liver clears olanzapine mainly by glucuronidation and through CYP1A2, while erythromycin inhibits a different enzyme, CYP3A4 (olanzapine and erythromycin labels).
Symptoms
QT prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG). The danger is ventricular arrhythmia: torsade de pointes, ventricular tachycardia, ventricular fibrillation and even sudden death (olanzapine and erythromycin labels). An arrhythmia episode presents as palpitations, dizziness or fainting. The risk is higher in older people and with congenital long QT syndrome, congestive heart failure, cardiac hypertrophy, low potassium or magnesium, clinically relevant bradycardia and coronary artery disease (olanzapine and erythromycin labels).
Management
Use the combination with caution: the European olanzapine label and the Spanish erythromycin labels ask for caution with any drug that prolongs the QT interval (olanzapine label, European Medicines Agency, EMA, and erythromycin labels, Spanish Agency of Medicines and Medical Devices, AEMPS). Take particular care in older people and in congenital long QT syndrome, congestive heart failure, cardiac hypertrophy and low potassium or magnesium (olanzapine label, EMA). The olanzapine label suggests considering a lower starting dose only with CYP1A2 inhibitors such as fluvoxamine or ciprofloxacin (olanzapine label, EMA). The documents give no dose adjustment for erythromycin. Do not give erythromycin to patients with a history of QT prolongation or ventricular arrhythmia, including torsade de pointes, or with low potassium or magnesium (erythromycin labels, AEMPS). Use erythromycin with caution in coronary artery disease, severe heart failure, conduction disorders, clinically relevant bradycardia and in older people (erythromycin label, AEMPS). Check blood electrolytes when there is a risk of imbalance, for example with vomiting and diarrhoea or in patients taking diuretics (erythromycin label, AEMPS). The Spanish label of one intravenous erythromycin product (Panpharma, registration number 79380) lists use with certain QT-prolonging neuroleptics among its contraindications without naming them. The labels of the original intravenous product and of oral forms ask only for caution with such drugs (erythromycin labels, AEMPS). The Panpharma label does not name olanzapine, and the olanzapine labels give no grounds to count it among these neuroleptics: in clinical trials olanzapine did not differ significantly from placebo in QT changes or related cardiac events (olanzapine labels). Before prescribing erythromycin, weigh the benefit of treatment against the risk of cardiac complications (erythromycin labels, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Zyprexa (olanzapine) prescribing information (2009)
- AEMPS: Ficha técnica: Eritromicina (nº registro 79380), sección 4.3 (2025)– AEMPS, CIMA, nº registro 79380, sección 4.3
- AEMPS: Ficha técnica: Eritromicina (nº registro 57474), sección 4.4 (2024)– AEMPS, CIMA, nº registro 57474 (Pantomicina 500 mg comprimidos), revisión 05/2024, secciones 4.3, 4.4 y 4.5
- FDA: E.E.S. (erythromycin ethylsuccinate) prescribing information (2025)– FDA, DailyMed, Carnegie Pharmaceuticals LLC, setid 91479d92-3bf3-4eb3-81bd-8ce4956d4347, revised 02/2025, Contraindications, Warnings – QT Prolongation, Precautions – Drug Interactions
- AEMPS: Ficha técnica: Eritromicina (nº registro 55771), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55771 (Pantomicina 1 g polvo para solución para perfusión), revisión 09/2025, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Olanzapina (EU/1/99/125), sección 4.4 (2026)– EMA, Zyprexa Velotab 10 mg comprimidos bucodispersables (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 99125002, consultada 10/2026, secciones 4.3, 4.4, 4.5, 4.8 y 5.2